BR112018005833A2 - compostos e métodos para inibir jak - Google Patents

compostos e métodos para inibir jak

Info

Publication number
BR112018005833A2
BR112018005833A2 BR112018005833-5A BR112018005833A BR112018005833A2 BR 112018005833 A2 BR112018005833 A2 BR 112018005833A2 BR 112018005833 A BR112018005833 A BR 112018005833A BR 112018005833 A2 BR112018005833 A2 BR 112018005833A2
Authority
BR
Brazil
Prior art keywords
methyl
compounds
ethyl
methods
inhibiting jak
Prior art date
Application number
BR112018005833-5A
Other languages
English (en)
Other versions
BR112018005833B1 (pt
Inventor
Birgitta Margareta Åstrand Annika
Patrick Grimster Neil
Kawatkar Sameer
Grant Kettle Jason
K. Nilsson Magnus
Lys Ruston Linette
Su Qibin
Marie Vasbinder Melissa
James Winter-Holt Jon
Wu Dedong
Yang Wenzhan
Grecu Tudor
Mccabe James
Donald Woessner Richard
Edmundo Chuaqui Claudio
Original Assignee
Dizal (Jiangsu) Pharmaceutical Co., Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal (Jiangsu) Pharmaceutical Co., Limited filed Critical Dizal (Jiangsu) Pharmaceutical Co., Limited
Publication of BR112018005833A2 publication Critical patent/BR112018005833A2/pt
Publication of BR112018005833B1 publication Critical patent/BR112018005833B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

são descritos compostos de fórmula (i) e composições farmacêuticas compreendendo tais compostos, e seus métodos / usos, por exemplo, para tratar uma doença relacionada com jak, tal como câncer, caquexia de câncer ou um distúrbio imunológico, onde r1 é metila ou etila; r2 é selecionado a partir de metila, etila, metóxi e etóxi; r3 é selecionado a partir de hidrogênio, cloro, flúor, bromo e metila; r4 é selecionado a partir de metila, etila e -ch2och3; r5 e r6 são, cada um, individualmente, metila ou hidrogênio; e r7 é selecionado a partir de metila, etila, -(ch2)2oh e -(ch2)2och3, ou um seu sal farmaceuticamente aceitável.
BR112018005833-5A 2015-09-25 2016-09-22 Composto, sal farmaceuticamente aceitável, composição farmacêutica e uso do composto BR112018005833B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562232629P 2015-09-25 2015-09-25
US62/232,629 2015-09-25
PCT/EP2016/072616 WO2017050938A1 (en) 2015-09-25 2016-09-22 Compounds and methods for inhibiting jak

Publications (2)

Publication Number Publication Date
BR112018005833A2 true BR112018005833A2 (pt) 2018-10-16
BR112018005833B1 BR112018005833B1 (pt) 2023-10-10

Family

ID=56979589

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018005833-5A BR112018005833B1 (pt) 2015-09-25 2016-09-22 Composto, sal farmaceuticamente aceitável, composição farmacêutica e uso do composto

Country Status (18)

Country Link
US (5) US9714236B2 (pt)
EP (2) EP4219482A1 (pt)
JP (1) JP6767491B2 (pt)
KR (1) KR20180058719A (pt)
CN (3) CN111646980B (pt)
AR (1) AR106138A1 (pt)
AU (1) AU2016328764B2 (pt)
BR (1) BR112018005833B1 (pt)
CA (1) CA2995430C (pt)
DK (1) DK3353168T3 (pt)
ES (1) ES2956642T3 (pt)
HK (1) HK1259422A1 (pt)
MX (1) MX2018003590A (pt)
PT (1) PT3353168T (pt)
RU (1) RU2760359C2 (pt)
TW (1) TWI740843B (pt)
WO (1) WO2017050938A1 (pt)
ZA (1) ZA201800782B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018003590A (es) * 2015-09-25 2018-11-29 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos y metodos para la inhibicion de jak.
US10513509B2 (en) 2016-05-26 2019-12-24 Recurium Ip Holdings, Llc EGFR inhibitor compounds
KR102585048B1 (ko) * 2017-01-17 2023-10-05 아스트라제네카 아베 Jak1 선택적 억제제
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
JP7422732B2 (ja) * 2018-07-18 2024-01-26 アストラゼネカ・アクチエボラーグ Ｊａｋ阻害化合物のキシナホ酸塩
CA3113732C (en) * 2018-09-21 2023-07-11 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Aromatic heterocyclic compound with kinase inhibitory activity
KR102195348B1 (ko) * 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3134174A1 (en) * 2019-04-19 2020-10-22 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Jak1 selective kinase inhibitor
CN110627775A (zh) * 2019-10-24 2019-12-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN111961037B (zh) * 2020-09-17 2021-09-21 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的药物化合物
WO2022111499A1 (zh) * 2020-11-26 2022-06-02 深圳铂立健医药有限公司 一种酰胺化合物、药物组合物及其应用
CA3213134A1 (en) * 2021-03-11 2022-09-15 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2332940T3 (pl) * 2004-03-30 2013-03-29 Vertex Pharma Azaindole użyteczne jako inhibitory JAK i innych kinaz białkowych
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
BRPI0618011A2 (pt) 2005-10-28 2011-08-16 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
KR20080110998A (ko) * 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
AU2007333394C1 (en) * 2006-12-08 2011-08-18 Novartis Ag Compounds and compositions as protein kinase inhibitors
CN102482277B (zh) * 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
EA025520B1 (ru) * 2009-05-22 2017-01-30 Инсайт Холдингс Корпорейшн N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US20130225615A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
AU2011328237A1 (en) * 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
BR112013012502A2 (pt) * 2010-11-19 2019-03-06 Incyte Corporation pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
WO2012116247A1 (en) 2011-02-25 2012-08-30 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
MY165963A (en) * 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
PL2830662T3 (pl) 2012-03-29 2019-02-28 The Trustees Of Columbia University In The City Of New York Sposoby leczenia zaburzeń utraty włosów
MX2018003590A (es) * 2015-09-25 2018-11-29 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos y metodos para la inhibicion de jak.

Also Published As

Publication number Publication date
CN111606893A (zh) 2020-09-01
WO2017050938A1 (en) 2017-03-30
US20190092760A1 (en) 2019-03-28
US20220119372A1 (en) 2022-04-21
EP3353168A1 (en) 2018-08-01
CN111848586A (zh) 2020-10-30
AU2016328764B2 (en) 2020-07-09
CN111646980B (zh) 2021-08-27
US20210078981A1 (en) 2021-03-18
JP2018529770A (ja) 2018-10-11
RU2760359C2 (ru) 2021-11-24
TWI740843B (zh) 2021-10-01
ES2956642T3 (es) 2023-12-26
EP4219482A1 (en) 2023-08-02
AR106138A1 (es) 2017-12-13
CN111606893B (zh) 2021-05-04
KR20180058719A (ko) 2018-06-01
US20170320857A1 (en) 2017-11-09
CN108368091B (zh) 2020-08-11
MX2018003590A (es) 2018-11-29
RU2018112993A3 (pt) 2020-01-30
ZA201800782B (en) 2018-12-19
US9714236B2 (en) 2017-07-25
CN111646980A (zh) 2020-09-11
BR112018005833B1 (pt) 2023-10-10
US10167276B2 (en) 2019-01-01
EP3353168B1 (en) 2023-08-30
JP6767491B2 (ja) 2020-10-14
US10654835B2 (en) 2020-05-19
DK3353168T3 (da) 2023-10-02
HK1259422A1 (zh) 2019-11-29
RU2018112993A (ru) 2019-10-28
AU2016328764A1 (en) 2018-02-22
CN108368091A (zh) 2018-08-03
US11247983B2 (en) 2022-02-15
PT3353168T (pt) 2023-09-20
US20170088543A1 (en) 2017-03-30
CA2995430C (en) 2023-07-11
CA2995430A1 (en) 2017-03-30
TW201730186A (zh) 2017-09-01

Similar Documents

Publication Publication Date Title
BR112018005833A2 (pt) compostos e métodos para inibir jak
EA201691302A1 (ru) Новые гетероциклические соединения
EA201792619A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
EA201791011A1 (ru) 3-ЗАМЕЩЕННЫЕ 5-АМИНО-6H-ТИАЗОЛО[4,5-d]ПИРИМИДИН-2,7-ДИОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИРУСНЫХ ИНФЕКЦИЙ
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
TR201904658T4 (tr) Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları.
EA201691167A1 (ru) Аналоги кортистатина, их синтез и применения
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
BR112017000550A2 (pt) compostos antiproliferativos e métodos de uso dos mesmos
MX2016014728A (es) Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b.
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201791304A1 (ru) Производные изохинолина для лечения вич
ECSP18012103A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
MX2019002438A (es) Compuestos triciclicos fusionados de piridazinona utiles para tratar infecciones de orthomyxovirus.
BR112017007563A2 (pt) compostos atropisômeros tricíclicos
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
UY36263A (es) Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso
MY182564A (en) 1, 2-substituted cyclopentanes as orexin receptor antagonists
BR112017008103A2 (pt) composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo.
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
EA201591456A1 (ru) Макроциклические и бициклические ингибиторы вируса гепатита с
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA201691413A1 (ru) Селективные антагонисты nr2b

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/09/2016, OBSERVADAS AS CONDICOES LEGAIS